Black Rock Inc. Sellas Life Sciences Group, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 430,368 shares of SLS stock, worth $602,515. This represents 0.0% of its overall portfolio holdings.

Number of Shares

430,368

Previous 278,218 54.69%

Holding current value

$602,515

Previous $281,000 82.21%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.06 - $1.63 $161,279 - $248,004	152,150 Added 54.69%	430,368 $512,000
Q1 2024 May 10, 2024	SELL	$0.51 - $1.55 $808 - $2,458	-1,586 Reduced 0.57%	278,218 $281,000
Q4 2023 Feb 13, 2024	SELL	$0.88 - $1.57 $696 - $1,243	-792 Reduced 0.28%	279,804 $296,000
Q3 2023 Nov 13, 2023	SELL	$1.42 - $1.83 $3,936 - $5,072	-2,772 Reduced 0.98%	280,596 $460,000
Q2 2023 Aug 11, 2023	BUY	$1.35 - $1.8 $29,544 - $39,393	21,885 Added 8.37%	283,368 $444,000
Q1 2023 May 12, 2023	BUY	$1.18 - $3.86 $1,862 - $6,091	1,578 Added 0.61%	261,483 $373,000
Q4 2022 Feb 13, 2023	BUY	$1.8 - $5.41 $6,561 - $19,719	3,645 Added 1.42%	259,905 $613,000
Q3 2022 Nov 14, 2022	SELL	$2.02 - $3.38 $2,514 - $4,208	-1,245 Reduced 0.48%	256,260 $517,000
Q2 2022 Aug 12, 2022	BUY	$2.14 - $4.15 $9,873 - $19,148	4,614 Added 1.82%	257,505 $574,000
Q1 2022 May 12, 2022	SELL	$4.73 - $7.18 $9,237 - $14,022	-1,953 Reduced 0.77%	252,891 $1.69 Million
Q4 2021 Feb 10, 2022	BUY	$5.36 - $9.53 $10,752 - $19,117	2,006 Added 0.79%	254,844 $1.41 Million
Q3 2021 Nov 09, 2021	BUY	$8.21 - $10.53 $2,939 - $3,769	358 Added 0.14%	252,838 $2.32 Million
Q2 2021 Aug 11, 2021	BUY	$7.19 - $13.71 $1.82 Million - $3.46 Million	252,480 New	252,480 $2.8 Million

Others Institutions Holding SLS

# of Institutions

Shares Held

5.7M

Call Options Held

1.67M

Put Options Held

74.7K

View Full List

About SELLAS Life Sciences Group, Inc.

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $28.8M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

More about SLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account